Introduction {#Sec1}
============

Appropriate diets and dietary supplements have the potential for use in the management of various metabolic syndromes and their complications \[[@CR1]\]. The fast food and/or junk food associated with many developed countries are having a drastic impact on the health of youth, as well as many adults with insufficient exercise. These types of food are typically rich in free fatty acids and contain a large amount of fatty substances, all of which promote diabetes, hypercholesterolemia, cancer, and other metabolic syndromes \[[@CR2]\]. In fact, three metabolic syndromes, cardiovascular diseases, diabetes, and cancer are the cause of up to 60--70% of mortality, worldwide \[[@CR3]\]. Hypercholesterolemia is an independent risk factor that alone or together with the consumption of unhealthy foods can accelerate the development of atherosclerosis and further resulted in atherosclerotic plaque \[[@CR4]\]. An increased generation of intracellular free radicals has also been demonstrated to play an important role in chronic inflammatory responses and atherosclerosis.

Several pharmacological agents are available, however, to manage hypercholesterolemia and atherosclerosis. One of the most widely used agents used for the therapeutic treatment of atherosclerosis are HMG-CoA inhibitors, known as statins \[[@CR1], [@CR5]\]. The long term use of statins, however, have been shown to be associated with undesirable side effects \[[@CR6]\]. For this reason, there is increased interest to identify alternatives to the use of statins that are reliable, effective, and have no or a low-level of adverse effects. In this regard, herbal formulations have been the centre of focus. Studies have demonstrated that some plants and their products exhibit hypolipidemic potential \[[@CR7]\].

For example, the desert plant, *Prosopis cineraria,* has been reported by several researchers to possess numerous medicinal properties, such as antidiabetic, hypoglycemic, anticancer, anti-inflammatory, anti-asthmatic, as well as a myriad of other pharmaceutical properties \[[@CR8], [@CR9]\]. Studies of this plant have also indicated that it possesses a number of potent bioactive compounds, including polyphenols, alkaloids, tannins, saponins, and flavonoids \[[@CR10]\]. Notably, the pod of *Prosopis cineraria* is a key ingredient panchkuta, a local Indian food dish with proposed healthy attributes without side effects. Therefore, a study was conducted to evaluate the inhibitory effect of an ethanolic extract of *Prosopis cineraria* pods on HMG-CoA reductase, and the antioxidant and anti-atherosclerotic potential of the extract. In-vitro, in-vivo*,* and *in-silico* assessments of the extract were conducted.

Materials and methods {#Sec2}
=====================

Pod procurement, authentication and extraction method {#Sec3}
-----------------------------------------------------

Pods of *Prosopis cineraria* (commonly known as Sangari) were obtained from a local herbal shop and authenticated by an expert in botany. The dried pods were ground with a mortar and pestle and a 70% ethanolic extract was obtained by soxhlation. A sticky extract was obtained and stored under desiccated conditions. Atorvastatin, a commonly prescribed statin, was purchased from a local pharmacy and used for comparative purposes (control). All chemicals were of reagent grade and purchased from Loba Chemie.

LC/MS chemical analysis {#Sec4}
-----------------------

LC-MS based metabolomics is a methodology used for characterizing the chemical fingerprint of herbal plant extracts. In our analysis, several mobile phase sequences were analysed to obtain the most comprehensive elucidation of chromatographic peaks \[[@CR11]\].

Gas chromatography with tandem mass spectrometry (GC-MS/MS) analysis {#Sec5}
--------------------------------------------------------------------

GC-MS analysis of the ethanol pod extract of *Prosopis cineraria* was conducted using a standard protocol. The sample was injected into a gas chromatograph interfaced with a mass spectrometer (GC-MS) \[[@CR12]\].

FTIR analysis {#Sec6}
-------------

An FTIR Spectrophotometer (Bruker Co., Germany) equipped with a standard detector and a germanium beam splitter, which was interfaced to a computer and analytical software, was utilized for the analysis. The KBr pellet technique was used to obtain a spectrum was in the mid IR region of 400--4000 cm^− 1^. The spectrum was characterized using the attenuated Total Reflectance (ATR) technique \[[@CR13]\].

In-vitro assessment of HMG -CoA reductase inhibition {#Sec7}
----------------------------------------------------

The inhibitory effect of the plant extract on HMG-CoA activity in vitro was determined using an HMG-CoA reductase assay kit (Sigma-Aldrich), which is based on a spectrometric measurement. The concentration of a standard HMG-CoA reductase stock solution was 0.50--0.70 nM. Different concentrations (5 μg/ml, 2.5 μg/ml,1.25 μg/ml, 0.62 μg/ml, and 0.32 μg/ml) of the ethanolic extract were mixed with a reaction mixture containing NADPH, HMG-CoA substrate, and HMGR. Pravastatin (Sigma Aldrich co.) was used as a positive control and distilled water served as a negative control \[[@CR12], [@CR14]\]. Inhibition activity was calculated according to the following equation.
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Where**:** **12.44** = εmM - the extinction coefficient for NADPH at 340 nm is 6.22 mM--1 cm--1. 12.44 represents the 2 NADPH molecules consumed in the reaction.**TV** = Total volume of the reaction in ml (1 ml for cuvettes and 0.2 ml for plates)**V** = Volume of enzyme used in the assay (ml)**0.6** = Enzyme concentration in mg-protein (0.50--0.70 mg P/ml)**LP** = Light path in cm (1 for cuvettes and 0.55 for plates).

Induction of hypercholesterolemia in rabbits and the experimental design {#Sec8}
------------------------------------------------------------------------

New Zealand, white, male rabbits, weighing approximately 1.5 ± 0.2 kg, were used as an animal model. They were acclimatized for 10 days in cages under controlled environmental conditions consisting of a 12-h light/dark regime and a temperature of 23 ± 2 °C. Food was supplemented with green leafy, seasonal vegetables and water. Hypercholesterolemia was induced by oral administration of 500 g of cholesterol powder mixed with 5 ml of coconut oil for 15 days along with a high fat diet \[[@CR15]\].

Animals were divided into four groups (*n* = 5) and the experimentation period was 60 days. Group 1: Control, treated with only distilled water for 60 days.Group 2: Hypercholesterolemic diet for 60 days.Group 3: Treatment with ethanolic *P. cineraria* pod extract (400 mg/kg/day) for 45 days after induction of hypercholesterolemia for 15 days.Group 4: Treatment with atorvastatin (0.25mg/kg) for 45 days after induction of hypercholesterolemia for 15 days.

Samples collections of in-vivo studies and planimetric study {#Sec9}
------------------------------------------------------------

After completion of the experiment at 60 days, overnight fasting animals were autopsied under mild anaesthesia. Blood samples were collected directly via a cardiac puncture and kept in both EDTA-coated test tubes and normal tubes for biochemical and hematological assessments, respectively. The vital organs (heart, aorta, kidney, and liver) were removed, fixed in formalin. and processed for histopathological examination. Planimetric studies of the aorta wall, lumen volume and atherosclerotic plaque were conducted using a Camera Lucida \[[@CR15]\].

Biochemical analyses {#Sec10}
--------------------

Serum was separated by centrifugation and stored at -20 °C. After thawing, assessments of total cholesterol \[[@CR16]\], triglyceride \[[@CR17]\], HDL -- cholesterol \[[@CR18]\], lipid profile \[[@CR19]\], glucose \[[@CR20]\], and other significant parameters were determined using standard methods.

Assessment of antioxidant properties {#Sec11}
------------------------------------

Serum LPO (lipid peroxidation) was determined by measuring thiobarbituric acid reactive substances (TBARS) and expressed as malondialdehyde (MDA) content, following the method of Ohkawa \[[@CR21]\]. Catalase and superoxide dismutase activity were assessed using the Aebi and Markland methods, respectively \[[@CR22]\].

Molecular docking {#Sec12}
-----------------

Molecular docking of HMG-CoA reductase (PDB:1DQ9) with Pravastatin (Standard Drug, Pubchem CID: 16759173) and the dominant phytocompounds in the ethanolic extract, i.e. Prosopilosine (Pubchem CID: 45269734), Prosogerin A (Pubchem CID: 44257586), Cinerin C (Pubchem CID: 101485482), β- Sitosterol (Pubchem CID: 222284), and Gallic Acid (Pubchem CID: 370) were conducted using Autodock 4.2. Water molecule and other co-factors were removed from the target molecule, while hydrogen atoms were added. Ligand was also prepared and docked into the active/ binding site of the target molecule \[[@CR23]\].

Statistical analysis {#Sec13}
--------------------

Results of the biochemical assessments, organs weights, and planimetric studies are expressed as a mean ± standard error of the mean (SEM) and statistical differences were determined by ANOVA and post hoc mean separation tests*.*

Results {#Sec14}
=======

In-vitro HMG-CoA reductase inhibition assay {#Sec15}
-------------------------------------------

The different concentrations of plant extract and the standard inhibitor exhibited a 67.1 and 97.5% level of inhibition of HMG-CoA activity, respectively, as indicated by the product rate per minute, were calculated using the described formula (Figs. [1](#Fig1){ref-type="fig"}a and b). Fig. 1**a** HMG -- CoA reductase Inhibition potential of Pravastatin. **b** HMG -- CoA reductase Inhibition potential of ethanolic pod extract of *Prosopis cineraria*

### LC-MS, GC-MS, and FTIR spectroscopy phytochemical analysis {#Sec16}

Using data from the literature and METLIN software, the masses of the constituents were identified based on the monoisotopic mass of the alleged compounds as M and M + H ion using QTOF mass hunter software. The default range for mass documentation was kept above a 100 m/z ratio. The mass spectra exhibited five major peaks in the pod extract (Table [1](#Tab1){ref-type="table"}and Fig. [2](#Fig2){ref-type="fig"}). The GC/MS data also revealed the presence of 3-O-Methyl-D-Glucose (Table [2](#Tab2){ref-type="table"} & Fig. [3](#Fig3){ref-type="fig"}). The functional groups of phytoconstituents in the mid IR region of a 400--4000 cm^−1^wave length were also annotated (Table [3](#Tab3){ref-type="table"} and Fig. [4](#Fig4){ref-type="fig"}). Table 1Identified phytocompounds of pod extract of *P. cineraria* by UPLC-QTOF analysisS. No.Identified compoundMonoisotopic massRetention time (min)1Cinnerin C402.16814.52Prosopilosine629.58612.23Prosogerin A312.06313.24β- Sitosterol412.37112.95Gallic Acid170.0226.9 Fig. 2Phytochemical analysis of UPLC chromatogram of ethanolic pod extract of *Prosopis cineraria* of LCMS analysis Table 2Identified phytocompounds of pod extract of *P. cineraria* by GC/MS analysisS. No.Identified compoundMonoisotopic massRetention time (min)13-O-Methyl-D-Glucose292317.419 Fig. 3Phytochemical analysis GC/MS of ethanolic pod extract of *Prosopis cineraria* Table 3FTIR -- analysis of ethanolic pod extract of *Prosopis cineraria*S. NoWavelengthFunctional group1.3163.08CH, NH2.3020.30CH3.2935.91CH4.2876.19= CH35.1715.41C=O (carbonyl group)6.1616.00C=C7.1355.44Nitro8.1224.06C-O9.1128.73C-O10.1028.13Alkyl halides(R-Cl)11.910.97Alkenes12.846.69Alkyl halides (R-Cl)13.735.35Aromatic compounds14.643.05Alkyl halides Fig. 4Phytochemical analysis by FTIR of ethanolic pod extract of *Prosopis cineraria*

### Lipid profile {#Sec17}

The treatment of rabbits with the ethanolic extract of *Prosopis cineraria* pods resulted in significant reductions in total cholesterol, LDL-cholesterol, triglyceride, VLDL relative to the other treatment groups (Table [4](#Tab4){ref-type="table"}). Table 4Lipid Profile of ethanolic pod extract of *Prosopis cineraria* treatmentTreatment groupTotal cholesterol (mg/dl)HDL cholesterol (mg/dl)LDL Cholesterol (mg/dl)VLDL Cholesterol (mg/dl)Triglycerides (mg/dl)Control (Gr.1)59.5 ± 2.1121.03 ± 2.920.69 ± 1.5717.78 ± 1.0669.87 ± 2.05Hypercholesterolemic (Gr.2)1216.5 ± 49.3^c^167.15 ± 8.55^c^1022 ± 66.41^c^26.54 ± 8.56^c^84.7 ± 5.2 ^c^Ethanolic pod extract of *P. cineraria* (Gr.3)67.01 ± 4.9 ^c,\ g^20.15 ± 2.5 ^c,\ g^21.65 ± 2.1 ^c,\ g^24.77 ± 1.5 ^c,\ g^94.5 ± 11.57 ^c,\ g^Atorvastatin (Gr.4)80.80 ± 4.9 ^c,\ g^15.77 ± 1.75 ^c,\ g^46.24 ± 7.8 ^c,\ g^18.74 ± 4.42 ^c,\ g^74.13 ± 2.5 ^c,\ g^Data are means ± S.E.M. (*n*=8); a, *P* ≤ 0.05 and c, *P* ≤ 0.001 as compared to the respective control values and g, *P* ≤ 0.001 as compared to the respective values of the Chol diet fed group

### Effect on antioxidant status {#Sec18}

The MDA content, which is an indicator of lipid peroxidation, was significantly higher (*P* ≤ 0.001) in the hypercholesterolemic group compared to the control group (distilled water). However, a significant reduction in MDA content was observed in the rabbits treated with the ethanolic extract. A significant increase (P ≤ 0.001) in serum SOD and catalase was also observed in the group of hypercholesterolemic rabbits treated with the ethanolic plant extract, relative to the untreated group of hypercholesterolemic rabbits. (Fig. [5](#Fig5){ref-type="fig"}). Fig. 5Serum antioxidants levels of ethanolic pod extract of *Prosopis cineraria* in treated groups. (Data are means ± S.E.M. (*n* = b8); a, *P* ≤ 0.05 and c,. *P* ≤ 0.001 as compared to the respective control values and g, *P* ≤ 0.001 as compared to the respective values of the Chol diet fed group)

### Histopathology {#Sec19}

The histological analysis of the aorta revealed three layers, i.e. intima, media, and adventitia, with enlarged lumen volume in the control group (Fig. [6](#Fig6){ref-type="fig"}a). In contrast, a bulging structure of atherosclerotic plaque, and reduced thickened media and lumen volume was observed in the aorta of the hypercholesterolemic rabbits (Fig. [6](#Fig6){ref-type="fig"}b). Treatment of hypercholesterolemic rabbits with either *Prosopis cineraria* pod extract or atorvastatin resulted in a significant reduction in atherosclerotic plaque and an increase in lumen volume; as well as reconstituted layer thickness of the intima, media, and adventitia layers (Fig. [6](#Fig6){ref-type="fig"}c and d). Fig. 6**a** Vehicle control (Gr. 1): Microphotograph of thoracic aorta exhibiting normal histology with aorta wall consists of intima, media and adventitia. (200x H&E). **b** Hypercholesterolemic control (Gr. 2): Microphotograph of thoracic aorta exhibiting atherosclerotic lesions with formation of plaque indicating by arrow, thickened intima contained foam cells and extracellular lipid (200x H&E). **c** Ethanolic *Propopis cineraria* pod extract treatment (Gr. 3): Microphotograph of thoracic aorta depicting regression in plaque indicating by arrow and normalcy in intima and media (200x H&E). **d** Atorvastatin treatment (Gr. 4): Microphotograph of thoracic aorta describing regression in plaque indicating by arrow and normal histoarchitecture of intima and media (200x H&E)

### Planimetric study {#Sec20}

Fatty plaque with foam cells were seen within the intima region of the aorta of hypercholesterolemic rabbits. In contrast, a significant regression in aortic plaque up to 73.55% along with increased lumen volume up to 23.46% and a somewhat normal histoarchitecture was observed in rabbits treated with the treatment of ethanolic extract of *Prosopis cineraria* pods, compared to the control and standard drug treated groups of rabbits (Table [5](#Tab5){ref-type="table"}). Table 5Planimetric Dimensions of Ascending Aorta of ethanolic pod Extract of *Prosopis cineraria* Treated Intact Rabbits (Mean of 5 Values ± SEM)Treatment GroupsTotal Wall AreaLumenPlaqueControl (Gr.1)49.42 ± 1.9950.74 ± 1.44NilHypercholesterolemic (Gr.2)78.16 ± 3.61^c^32.21 ± 2.52^c^18.59 ± 1.01 ^c^Ethanolic pod extract of *P. cineraria* (Gr.3)57.21 ± 5.01 ^c^44.11 ± 3.23 ^c,\ g^4.89 ± 1.38 ^c,\ g^Atorvastatin (Gr.4)53.29 ± 1.01^c,\ g^49.31 ± 2.44^c,\ g^1.31 ± 0.02 ^c,\ g^Data are means ± S.E.M. (*n* = 5); a *P* ≤ 0.05; b *P* ≤ 0.01; c *P* ≤ 0.001; and d nonsignificant as compared to the respective control values. g *P* ≤ 0.001 and h nonsignificant as compared to the respective values of the Chol diet fed group

### Molecular docking {#Sec21}

The molecular docking of HMG-CoA reductase with ligands (standard drug and phytoconstituents of the plant extract) exhibited significant affinity and molecular interactions with the target protein as indicated by the binding energy, number of H-bonds and bond lengths (Table [6](#Tab6){ref-type="table"} and Fig. [7](#Fig7){ref-type="fig"}a-e). Table 6HMG -CoA reductase molecular docking with standard drugs and phytoconstituents of ethanolic pod extract of *Prosopis cineraria*S. No.LigandBinding Energy (Kcal/mol)No. of H-bondsRMSDPositive control1.Pravastatin−7.021.82.Atorvastatin−7.522.4Phytoconstituents3.Cinnerin C−6.511.34.Prosogerin A−7.921.45.Gallic Acid−6.2206.Beta-sitosterol−6.811.9 Fig. 7**a** Interaction of Atorvastatin with target enzyme HMG -- CoA reductase. **b** Interaction of Pravastatin with target enzyme HMG -- CoA reductase. **c** Interaction of Prosogerin - A with target enzyme HMG -- CoA reductase. **d** Interaction of Prosopilosine with target enzyme HMG -- CoA reductase. **e** Interaction of β-sitosterol with target enzyme HMG -- CoA reductase

Discussion {#Sec22}
==========

Dietary approaches are frequently used for managing health problems, with specific diets being recommended for the therapeutic treatment of various ailments \[[@CR24]\]. Historical treatments are chiefly based on herbal formulations with their efficacy being dependent on the presence of active compounds within the herbal preparation and their bioreactivity \[[@CR24], [@CR25]\]. In contrast, improper diet is often the cause of several metabolic disorders and their resulting complications. In modern times, junk food and a fat rich diet have received considerable attention due to their role as a principle factor in hypercholesterolemia and obesity \[[@CR26]\]. In the present study, similar symptoms of these atherosclerosis were observed in healthy rabbits after they were subjected to oral administration of cholesterol supplements and a high fat diet. Hypercholesterolemia may result through various mechanisms which results in the progression of atherosclerosis in animal models and higher primates \[[@CR27]--[@CR29]\]. Atherosclerosis is now considered the principle reason for mortality and morbidity worldwide \[[@CR30]\]. Numerous therapies presently exist to combat atherosclerosis, such as statins which are HMG-CoA reductase inhibitors, bile acid sequestrants, fibrates, and niacin; all of which are designed to improve the lipid profile \[[@CR5]\]. However, these therapeutic agents are often associated with undesirable side effects. In particular, statins are an efficient therapy for treating hypercholesterolemia, through their ability to reduce cholesterol biosynthesis by targeting HMG-Co reductase activity; which is a rate limiting enzyme in the melvonate pathway \[[@CR31]\]. The long-term use of statins, however, can result in severe adverse side effects. In contrast, nutraceuticals often exhibit little to no side effects and have been used in the treatment of atherosclerosis, hypercholesterolemia, and various other ailments \[[@CR32]\].

In this regard, the desert region of western Rajasthan, India has a native plant, *Prosopis cineraria,* whose pods are used to make an herbal extract which is rich in potent phytochemicals \[[@CR8], [@CR9]\]. Bark tissues of *Prosopis cineraria* already have been previously demonstrated to have anti-atherosclerotic activity \[[@CR8], [@CR33]\]. In the present study, treatment of hypercholesterolemic rabbits with an ethanolic extract of *Prosopis cineraria* pods resulted in a significant reduction in plaque formation, as well as improvements in their lipid profiles. These results were similar to the those obtained by Ram and co-workers who demonstrated the anti-atherosclerotic activity of *Prosopis cineraria* and *Acacia senegal* bark extracts \[[@CR15], [@CR33]\]. It is plausible that these results are due to the presence of potent anti-atherosclerotic and hypocholesterolemic phytoconstituents that reduce lipids and necrotic material, support endothelial repair, or halt the proliferation of vascular smooth muscle cells \[[@CR34]--[@CR36]\]. Several mechanisms may be responsible for this therapeutic activity, such as a reduction in high-density lipoprotein cholesterol (HDL-C), destruction of foam cells and macrophages in lymph nodes, and the restoration of the endothelium by neighbouring cells or circulating progenitors \[[@CR32], [@CR37]\]. The alteration in the lipid profile and the regression of atherosclerotic plaque by the plant extract was supported by results obtained in the in-vitro HMG-CoA reductase inhibition assay and *in-silico* evaluation conducted in previous studies \[[@CR38], [@CR39]\]. The phytoconstituents in the extract were analysed and identified by LCMS, GCMS, and FTIR; which validated the existence of several phytoconstituents identified functional groups that could potentially interact with target enzyme and serve as competitive inhibitors or analogues of substrates \[[@CR37], [@CR38], [@CR40]\].

Additionally, oxidative stress and the production of free radicals have been shown to induce degenerative changes that promote endothelial dysfunction and are thus involved in the pathogenesis of atherosclerosis and are also linked to other metabolic syndromes \[[@CR41], [@CR42]\]. In the present study, treatment of rabbits with the ethanolic extract increased antioxidant levels; including SOD and catalase activity. The reduction in oxidative stress and the general increase in antioxidant levels may be attributed to the presence of antioxidants in the plant extract and the ability of the phytoconstituents to generally boost the antioxidant system. Several studies have indicated that oxidation-reduction reactions play a vital role in atherogenesis; however, analysing the role of antioxidants only with respect to their reduction potential may be too narrow of a perspective. Park et al., (2015) reported that the α-asarone constituent in plant extracts of *Perilla frutescens* extracts exhibit a strong antioxidant capacity and avert the oxidation of LDL in vitro and in vivo \[[@CR43]\]. Additionally, the α-asarone also triggered the macrophage response to LXR and PPAR-γ agonists, by decreasing SR-B1 and increasing the interaction with ABCA-1 and ABCG-1. Thus, the efficacy of α-asarone could be attributed to both its antioxidant potential and its effect on lipid metabolism \[[@CR44]\]. It appears that a balance between oxidative stress and antioxidants is needed in the therapeutics used to treat metabolic syndromes. The antioxidant defense system in cells includes catalase, SOD, and GPx, which help in the degradation of NO \[[@CR45]\]. Hypercholesterolemia leads to a decrease in SOD and catalase levels \[[@CR46]\]. In the present study, treatment of rabbits with an ethanolic extract of *P. cineraria* pods resulted in a significant elevation in catalase and SOD levels, which may have been induced by the free radical scavenging activity properties of the phytoconstituents present in the plant extract. Our results also indicated that LPO (lipid peroxidation) was reduced in rabbits treated with the extract; which again confirms its role in scavenging reactive oxygen species (ROS). It is possible that these effects may be directly due to the free radical scavenging potential of the phytoconstituents in the ethanolic extract \[[@CR47]\]. Collectively, results of the present study demonstrate that the phytoconstituents contained in an ethanolic extract of *Prosopis cineraria* pods inhibits HMG -- CoA reductase activity and reduces the level of atherosclerotic plaque in hypercholesterolemic rabbits.

Conclusion {#Sec23}
==========

This present study demonstrated that an ethanolic extract of *Prosopis cineraria* pods can reduce serum cholesterol when fed to hypercholesterolemic rabbits. The extract also reduced the level of atheromatous plague in the aorta. Notably, the extract can improve antioxidant enzyme activity and inhibits HMG-Co reductase activity. Therefore, the use of an ethanolic extract of *Prosopis cineraria* pods should be further investigated as an alternative therapeutic agent to statins and other drugs, but one that does not have adverse side effects for the treatment of cardiovascular diseases.
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